BioSpace - Idera Pharmaceuticals, Inc. News, Search Jobs, Events

BioSpace Login

Enter your BioSpace account email address and password to log in now.

Email Address

Password

Keep me logged in

Close Window

Forgot Your Password? | Privacy Statement

NEW MEMBER SIGN UP

Display Name

Email Address

Password

Password again

Zip

Country

Close Window

Privacy Statement

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

Search the Site

Community Login

What is this?

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

Idera Pharmaceuticals, Inc.

167 Sidney Street

Cambridge Massachusetts 02139 U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592

View Clinical Trials from BioPharm Insight

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.

Key Statistics

Email: info@iderapharma.com
Ownership:
Web Site: Idera Pharmaceuticals, Inc.
Employees:
Symbol: IDRA

Industry
Biotechnology
Pharmaceutical

Company News

Idera Pharmaceuticals, Inc. (IDRA) Reports Third Quarter 2009 Financial Results and Provides Pipeline Update 11/5/2009 9:16:30 AM More...

Idera Pharmaceuticals, Inc. (IDRA) Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009 11/3/2009 9:32:11 AM More...

Idera Pharmaceuticals, Inc. (IDRA) Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use 10/26/2009 9:13:07 AM More...

Idera Pharmaceuticals, Inc. (IDRA) Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model 10/19/2009 8:33:31 AM More...

Idera Pharmaceuticals, Inc. (IDRA) to Present at 8th Annual Biotechnology Industry Organization (BIO) Investor Forum 10/16/2009 8:08:43 AM More...

Idera Pharmaceuticals, Inc. (IDRA) Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection 10/7/2009 8:08:07 AM More...

Idera Pharmaceuticals, Inc. (IDRA) to Present at 11th Annual Massachusetts Biotechnology Investors Forum 10/1/2009 9:35:27 AM More...

Idera Pharmaceuticals, Inc. (IDRA) Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma 9/25/2009 8:32:52 AM More...

Idera Pharmaceuticals, Inc. (IDRA) Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva(R) and Avastin(R) in Non-Small Cell Lung Cancer 9/23/2009 9:10:57 AM More...

Idera Pharmaceuticals, Inc. (IDRA) to Present at UBS Global Life Sciences Conference 9/15/2009 9:31:56 AM More...

1